Hexadecylphosphocholine: a new and selective antitumor drug by Eibl, H. & Unger, C.
Cancer Trmtnent Reviews (19901 17, 233-242 
Hexadecylphosphocholine: a new and selective 
antitumor drug 
H. Eibl* and C. Ungert 
* Max-Planck-Institute.for Biophysical Chemistry and t Division of Hematology/Oncology, 
Department of Internal Medicine, University Hospital Giittingen, D-3400 Giittingen, Germany 
Introduction 
In the 196Os, the first evidence was obtained at the Max-Planck-Institute in Freiburg 
that lysolecithins, as a consequence of their high affinity to the cell membrane, not only 
cause changes in permeability (7, 16), but are also catalysts in more complex cellular 
events. Synthetic (ether)-lysolecithins have been shown to be capable of influencing the 
mammalian body’s own immune system (13). The effects obtained were structurally de- 
pendent. (Ether)-lysolecithins with long-chain alkyl residues (Cl6 and longer) led to immu- 
nostimulation. Those with short-chain alkyl chains (C,, and shorter), led to immuno- 
suppression. The lack of (ether)-cleaving enzymes in carcinomas (17) was particularly 
interesting because of the possible use of (ether)-lysolecithins in the therapy of malignant 
tumors. This finding led to the hypothesis that (ether)-lysolecithins could be metabolized 
in normal cells, but not in malignant tissues. Based on differences in the enzyme content 
of neoplastic cells and normal cells, selective activity of the (ether)-lysolecithins towards 
tumor cells might be expected. In 1982, we started our investigations on the antitumor 
efficacy of phospholipids and analogs. 
From (ether)-lysolecithins to alkylphosphocholines 
Numerous studies have shown that 1-0-octadecyl-2-O-methyl-rut-glycero-3-pho- 
sphocholine inhibits the growth of methyl nitrosourea induced breast carcinomas in the 
rat. Surprisingly, the effect of these substances was not very selective (3). Therefore, the 
importance of the (ether)-cleaving enzyme as a selective detoxifying agent in normal 
cells was put in doubt. It was the aim of the present investigations to determine through 
systematic analysis of the metabolism of structurally modified (ether)-lysolecithins which 
structures might be selective. The study was expected to provide information on the 
minimal structural requirements for antitumor efficacy and, if possible, on which of these 
elements were responsible for selectivity. Our investigations were the first to discover a 
correlation between chemical structure, antitumor efficacy and selectivity. Of major 
importance for these investigations was the development of simple methods for the prep- 
aration of lysolecithins and analogs (6, 7, 8, 2 1). 
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Figure 1. Chemical structure of (ester)- and (ether)-lysolecithins. The arrows indicate attack sites for phospholipid 
metabolizing enzymes: (a), phospholipase A,; (b), acyltransferase; (c), phospholipase C; (d), phospbolipase D; 
(e), 0-alkylglycerol monooxygenase; (f), transesterase. The squared-in area characterizes structural elements 
which are essential for antineoplastic activity. 
Figure 1 shows a series of lysolecithins whose structures are purposefully varied. For 
instance, compounds I and II are naturally occurring intermediates and non-toxic. With 
compound III, 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine, we achieved 
compounds which are almost metabolically stable. This stability generates anti-neoplastic 
activity in vivo (3). 
The antitumor efficacy of l-O-octadecyl-2-O-methyl-ruc-glycero-3-phosphocholine 
(III) compared to substances I and II is not explained solely on the basis of its physical 
properties. For instance, hemolytic activity and critical micelle concentration of these 
compounds with values of about 10m5 M differ strongly. It is more likely that substrate 
properties towards phospholipid metabolizing enzymes are responsible for the antitumor 
activity. It follows from Figure 2 that 1-palmitoyl-sn-3-glycero-phosphocholine (I) in 
microsomes derived from rat livers can, in the presence of oleoyl-CoA, be rapidly trans- 
formed into 1 -palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (I) and thereby detoxified. 
The enzymes responsible for this are the acyltransferases (5). Surprisingly, and contrary 
to the current views, acyltransferases cannot acylate and, therefore, cannot detoxify the 
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F&re % Microsomal protein from rat livers (0.15 mg) was incubated with 170 nmol (3H)-labelled l-palmitoyl- 
sn-glycero-3-glycero-phosphocholine (&f-value 0.17) and 50 nmol (I%)-labelled oleoyl-CoA at 37°C in 1 ml 
buffer at pH 7.4. According to the times given, the reaction was stopped by the addition of formic acid. After 
freeze-drying, the residue was extracted with chloroform, applied to silica gel plates and developed using the 
solvent system chloroform/methanol/glacial acetic acid/water 100 : 60 : 20 : 5 (per vol.). Increasing amounts of 
radioactive produrt formed in a time-dependent manner with the RJvalue 0.40, 1-palmitoyl-2-oleoyl-sn-glycero- 
3-phosphocholine. 
corresponding (ether)-lysolecithins, e.g. 1-O-octadecyl-sn-glycero-3-phosphocholine (II). 
As shown in Figure 3, under the optimal acylating conditions worked out for l-palmitoyl- 
sn-3-glycero-phosphocholine (I), no product is formed with I-O-octadecyl-sn-glycero-3- 
phosphocholine in the presence ofoleoyl-CoA (15). (Ether)-lysolecithins are not substrates 
for acyl-CoA dependent acyltransferases. However, detoxification is still possible by means 
ofother enzymes. For instance (ether)-lysolecithins (II) can be cleaved by 0-alkylglycerol 
monooxygenases or possibly via other acylating enzyme systems of the cell. 
We have, however, found enzymes which can detoxify 1-O-octadecyl-sn-glycero-3- 
phosphocholine in the absence of acyl-CoA. The enzymes are transesterases which transfer 
fatty acids from inositolphosphatides into the 2-position of (ether)-lysolecithins (15). These 
results are summarized in the deacylation-reacylation cycles for 1,2-diacyl-sn-glycero-3- 
phosphocholine and l-0-alkyl-2-acyl-alkyl-sn-glycero-3-phosphocholine (Figure 4). Both 
groups of substances are turned into the corresponding single-chain compounds by phos- 
pholipase A,. Reacylation, however, takes place via various enzymes and with different 
cosubstrates. 
In comparison to the (ester)- and (ether)-lysolecithins with free hydroxyl groups in 
the sn-2-glycerol position which can be acylated, 1-0-octadecyl-2-O-methyl-glycero-3- 
phosphocholine (III) is certainly no substrate for acylating enzymes. The hydroxyl group 
in the sn-2 position is blocked by a methyl group. Remarkably, this compound is not a 
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Figure 3. The conditions for incubation and the type of processing are as stated in Figure 2. However, (3H)- 
labelled I-0-octadecyl-sn-glycero-3-phosphocholine (Rf-value 0.17) was used instead of the (ester)-lysolecithin. 
Product formation was no longer observed. Acyl-CoA dependent acyltransferases cannot acylate (ether)- 
lysolecithins. 
substrate for 0-alkylglycerol monooxygenases. We were able to prove this with newly 
developed methods (10, 11,20). The difference in the enzyme contents of tumor compared 
to normal cells cannot lead to a selective destruction of tumor tissue because 1 -O-octadecyl- 
2-0-methyl-sn-glycero-3-phosphocholine and the enantiomer 3-O-octadecyl-2-O-methyl- 
sn-glycero-1-phosphocholine are lacking the necessary substrate properties for O-alkyl- 
glycerol monooxygenases. The selective activity that has been discussed in connection 
with differences in the enzyme content of tumor and normal cells for 0-alkylglycerol 
monooxygenases (2, 13) has not received experimental confirmation ( 18). 
From our experimental findings on the substrate properties of these substances, on their 
metabolism in cell cultures and in various organs, including rat tumors, it is possible to 
say that it is these missing substrate properties for alkylglycerol monooxygenases that are 
the critical requirements for tumor growth inhibition produced by these compounds. Only 
1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine has antineoplastic properties 
and, at the same time, is a marginal substrate for phospholipase C and D. In addition, a 
transfer of phosphocholine to diacylglycerol is observed (Figure 5). The analogous com- 
pound with an enlarged distance between phosphate and trimethylammonia (IV), as 
shown in Figure 6, has no substrate properties for phospholipid metabolizing enzymes and 
is inactive. Substance V, 1-O-octadecyl-propandiol-3-phosphocholine is a substrate for 
0-alkylglycerol monooxygenase and can therefore be detoxified. Our prediction from 
these observations is that the minimal structural elements for antineoplastic activity are 
given by an alkanol of chain length Cl6 to Cl8 attached to phosphocholine. 
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Figure 4. The different metabolism of 1,2-(diacyl)-lecithins and of I-0-(alkyl)-lecithins (deacylation-reacylation 
cycles). PLA,, phospholipase A,; PC, phosphocholine; PI, phosphatidylinositol; R,, R, and R,, alkyl residues. 
Hydrolysis with PLA, occurs independently ofan ester or ether function in the sn- 1 glycerol position. Reacylation 
of (ester)-lysolecithins is catalyzed by acyltransferases, reacylation of (ether)-lysolecithins by transesterases. 
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Figure 5. Metabolism of l-O-octadecyl-2-O-methyl-7ac-glycero-3-phosphocholine in Raji cell cultures. The cells 
were incubated with labelled l-O-octadecyl-2-O-methyl-rac-glycero-3-phospho-(1’C)-choline (OM-G-PC) and 
centrifuged off after 24, 28 and 72 h. After extracting the sediment with chloroform/methanol, the lipid extract 
was spread onto silica gel plates and developed with the developing solvent mixture of chloroform/methanol/ 
glacial acetic acid and water 100 : 60 : 20 : 5 (by volume). Increasing amounts of 1,2-(diacyl)-sn-glyccro-3-phos- 
pho-(‘%)-choline (1,2-diacyl-In-G-PC*) form in a time-dependent manner by direct transfer of the phospho- 
choline residue to diacylglycerol. 
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Figure 6. Chemical structure of (ether)-lysolecithins. The arrows indicate attack sites for phospholipid meta- 
bolizing enzymes: C, phospholipase C; D, phospholipase D; E, 0-alkylglycerol monooxygenase. The squared- 
in area contains structural elements which are essential for antineoplastic activity. 
Hexadecylphosphocholine: a new and selective antitumor drug 
Structural parameters that influence the antitumor activity of (ether)-lysolecithins suggest 
that the glycerol moiety is more of a disadvantage. This moiety mediates substrate prop- 
erties towards phospholipid-metabolizing enzymes such as acyltransferases, transesterases, 
phospholipases and alkylglycerol monooxygenases, enzymes which must be inhibited in 
order to achieve antineoplastic activity. Consequently, glycerol as a characteristic struc- 
tural element of phospholipid molecules can be eliminated. From our experience, the 
minimal structural elements for antineoplastic activity are alcohols with 16 or 18 carbon 
atoms which are esterified with a phosphocholine residue; this creates a whole new class 
of substances with antineoplastic activity: the alkylphosphocholines. We deal here only 
with one important representative of the alkylphosphocholines: hexadecylphosphocholine. 
Figure 7 compares 1-O-octadecyl-2-O-methyl-ruc-glycero-3-phosphocholine, hexadecyl- 
phosphocholine and hexadecylphospho-( N,N,N-trimethyl)butanolamine. As shown 
for similar compounds, all three substances have comparable physical properties with 
regard to their behavior in monomolecular films (4)) in critical micelle concentration ( 12) 
or in the critical concentration for hemolysis of erythrocytes (1, 16). Similar to I-O- 












Figure 7. Chemical structure of hexadecylphosphocholine and an analog with extended distance between 
phosphate and trimethylammonia. The arrow indicates sites of attack for phospholipid metabolizing enzymes: 
C, phospholipase C; D, phospholipase D. The squared-in area comprises structural elements which are essential 










Figure 8. Metabolism of hexadecylphosphocholine in Raji cell cultures. The cells were incubated with labelled 
hexadecylphospho-(‘%)-choline and prepared as described in Figure 5. Instead ofthe acidic system, a developing 
solvent system of chloroform/methanol/250/, ammonia 50 : 50 : 5 (by volume) was used. Increasing amounts of 
1,2-(diacyl)-lecithin were formed in a time-dependent manner which occurred through a direct transfer of the 
phosphocholine group to diacylglycerol (see schematic representation). 
octadecyl-2-0-methyl-rac-glycero-3-phosphocholine, hexadecylphosphocholine is a mar- 
ginal substrate for phospholipase C and D (Figure 8) and also antineoplastically effective. 
On the other hand, hexadecylphospho-(N,N,N-trimethyl)-butanolamine is lacking the 
substrate properties for the necessary phospholipases mentioned. In animal experiments, 
it has been ineffective against chemically induced, autochthonous mammary carcinomas. 
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Cyclophosphomide 147 mg/kg (Ix ix) 
He-PC: 31.6 mg/kg (daily p.o.1 
Figure 9. Comparison of the antineoplastic activity of hexadecylphosphocholine and cyclophosphamide on 
dimethylbenzanthracene-induced mammary carcinoma of the rat: 0, controls; X, cyclophosphamide (single 
intravenous application of the maximally tolerable dose of 147 mg/kg); h exadecylphosphocholine (oral admin- 
istration via a stomach tube: 31.6 mg/kg daily). Cyclophosphamide had a short-term tumorostatic effect. 
Administration of hexadecylphosphocholine led to complete remission within a period of 20 days without 
measurable side effects. 
This demonstrates that phosphocholine is a necessary prerequisite ofantineoplastic activity 
in alkylphosphocholines. 
Surprisingly, in the chemically induced mammary carcinoma models mentioned, 
hexadecylphosphocholine is superior to l-0-octadecyl-2-0-methyl-rat-glycero-3-phos- 
phocholine. For the first time, complete remissions were achieved in these difficult to treat 
models (9, 14). These recent experiments prove the tumoricidal activity of hexa- 
decylphosphocholine, whereas only a tumorostatic activity could be shown for l-O- 
octadecyl-2-0-methyl-rac-glycero-3-phosphocholine. The lack of bone marrow toxicity is 
useful for the long-term administration of this drug. The activity of hexadecylphos- 
phocholine is exemplified by its effect on the dimethylbenzanthracene-induced mammary 
carcinoma model. Figure 9 illustrates the activity of orally administered hexadecyl- 
phosphocholine versus a single, maximally tolerated intravenous injection of cyclo- 
phosphamide in tumor bearing rats. Cyclophosphamide shows a slight reduction in tumor 
weight after a period of 7 days compared to the controls. Hexadecylphosphocholine, on 
the other hand, causes complete remission after 20 days. The effect of hexadecylphospho- 
choline is also independent of the size of the original tumor. In all experiments to date, 
we have achieved complete remissions, independent of the original tumor size. 
First clinical experience 
The positive results of the first animal experiments on chemically induced rat mammary 
carcinoma led us to initiate clinical trials with hexadecylphosphocholine. Two forms of 
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administration were chosen for clinical use: oral and topical. Topical application was used 
for treating skin metastases of cutaneous metastatic breast cancer. The oral route was 
chosen to test the tolerability and efficacy of the substance on solid, metastatic tumors 
within the framework of a Phase I study. 
For topical application, hexadecylphosphocholine was taken up into a mixture of l-O- 
alkylglycerols of the alkyl chain lengths C, ( I-0-proplyglycerol), C6 (1-0-hexylglycerol), 
Cg (1-O-nonylglycerol) and water in such a way that the solution remained single-phase. 
1-O-alkylglycerols are membrane permeable amphilic molecules. This property allows 
them to change the permeability of membranes and also improves the penetration of 
cytostatics across the blood brain barrier (19). 
To date, 25 patients have been treated with this mixture of alkylglycerols and hexa- 
decylphosphocholine. All patients previously have had intensive therapy (chemo-, radio- 
or hormone therapy). The results of this treatment on the 22 evaluable patients are as 
follows: four had a complete remission, two had a partial remission and six were stable 
over a maximum period of 12 months. In the other 10 patients the treatment was 
apparently unsuccessful and their tumors progressed. 
The good local tolerability of the mixture was impressive. Cutaneous side-effects were 
mild: moderate dryness of the skin, epithelial scaling and in isolated cases, itching. In 
several cases, skin biopsies were taken which histologically showed normal skin architecture 
after treatment over several months. It should be stressed that no hematological toxicity 
or other changes in blood chemistry were observed. A multicenter Phase II study on the 
topical therapy of skin metastases is currently ongoing. In addition, we initiated a clinical 
Phase I study for oral application of hexadecylphosphocholine. 
Summary 
Interdisciplinary cooperation between basic and clinical research has resulted in the 
discovery and development of alkylphosphocholines, a new class of substances for the 
treatment of breast cancer. In contrast to most antitumor substances, the alkyl- 
phosphocholines do not attack the cell nucleus, but the cell membrane. This report presents 
a systematic study which, for the first time, provides a correlation between their chemical 
structure, antitumor efficacy and selectivity. Through an understanding of the metabolism 
of tumor growth inhibiting (ether)-lysolecithins, the minimal structural requirements for 
the antineoplastic efficacy of these substances have been obtained. This knowledge was 
used to identify molecular structures which are more effective and less toxic for the 
organism. 
The active principle derived from a study of (ether)-lysolecithins active as antitumor 
agents represents a new class of compounds: the alkylphosphocholines. As reported here, 
hexadecylphosphocholine is the most promising candidate of this group of compounds. It 
has an extremely selective action against chemically induced, autochthonous rat mammary 
carcinomas. No loss of activity was observed when comparing oral and intravenous 
administration. Particularly striking (and favorable for long-term therapy) is the fact that 
immunosuppression and hematotoxicity were not found at drug concentrations which lead 
to complete tumor remissions. Results obtained from animal experiments have been 
confirmed by preliminary clinical investigations. 
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